A Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal Malignancies

2015 ◽  
Vol 14 (1) ◽  
pp. 18-24.e1 ◽  
Author(s):  
Corina N. Oldenhuis ◽  
Walter J. Loos ◽  
Brooke Esteves ◽  
Leni van Doorn ◽  
Monette M. Cotreau ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Vegf Receptor ◽  
Gastrointestinal Malignancies ◽  
Phase Ib ◽  
Receptor Tyrosine Kinase Inhibitor

P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S182
Author(s):  
Catherine Wheeler ◽  
Hironobu Minami ◽  
Hiromichi Ebi ◽  
Makoto Tahara ◽  
Yasutsuna Sasaki ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Receptor Tyrosine Kinase ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Vegf Receptor ◽  
Receptor Tyrosine Kinase Inhibitor

scholarly journals The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

2017 ◽  
Vol 116 (11) ◽  
pp. 1402-1407 ◽  
Author(s):  
Rachna T Shroff ◽  
Mark Yarchoan ◽  
Ashley O'Connor ◽  
Denise Gallagher ◽  
Marianna L Zahurak ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Mek Inhibitor ◽  
Vegf Receptor ◽  
Receptor Tyrosine Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document